Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside

Neurotherapeutics

Volumn 6, Issue 4, 2009, Pages 713-737

  Rahn, Elizabeth J ^a   Hohmann, Andrea G ^a  

^a University of Georgia ^*  (United States)

Author keywords

chemotherapy; diabetes; Endocannabinoid; marijuana; multiple sclerosis; neuropathy

Indexed keywords

2 ARACHYDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AJULEMIC ACID; AMINOALKYLINDOLE; ANANDAMIDE; BAY 593074; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID; FATTY ACID AMIDASE INHIBITOR; JZL 184; JZL 194; L 29; N ARACHIDONOYL GLYCINE; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; OL 135; PALMITOYLETHANOLAMINE; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602;

ALLODYNIA; ARTICLE; BRACHIAL PLEXUS INJURY; CANNABIS SMOKING; CHRONIC PAIN; CLINICAL TRIAL; DEMYELINATION; DIABETES MELLITUS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERALGESIA; INTOXICATION; MULTIPLE SCLEROSIS; NERVE INJURY; NEUROPATHIC PAIN; NEUROPATHY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; STIMULUS RESPONSE; STREPTOZOCIN DIABETES; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

ANIMALS; CANNABINOIDS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; HUMANS; NEURALGIA; PERIPHERAL NERVOUS SYSTEM DISEASES; RECEPTORS, CANNABINOID;

EID: 70349333074     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.08.002     Document Type: Article

References (183)

1. Gaoni Y., and Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86 (1964) 1946-1947
2. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
3. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
4. Guindon J., and Hohmann A.G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153 (2008) 319-334
5. Ledent C., Valverde O., Cossu G., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
6. Buckley N.E., McCoy K.L., Mezey E., et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396 (2000) 141-149
7. Agarwal N., Pacher P., Tegeder I., et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10 (2007) 870-879
8. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11 (1991) 563-583
9. Matsuda L.A., Bonner T.I., and Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327 (1993) 535-550
10. Hohmann A.G., and Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90 (1999) 923-931
11. Malan Jr. T.P., Ibrahim M.M., Deng H., et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93 (2001) 239-245
12. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., and Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 92 (1995) 3376-3380
13. Ross R.A., Coutts A.A., McFarlane S.M., et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40 (2001) 221-232
14. Van Sickle M.D., Duncan M., Kingsley P.J., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
15. Gong J.P., Onaivi E.S., Ishiguro H., et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071 (2006) 10-23
16. Ashton J.C., Friberg D., Darlington C.L., and Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 396 (2006) 113-116
17. Beltramo M., Bernardini N., Bertorelli R., et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23 (2006) 1530-1538
18. Wotherspoon G., Fox A., McIntyre P., Colley S., Bevan S., and Winter J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135 (2005) 235-245
19. Devane W.A., Hanus L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
20. Mechoulam R., Ben-Shabat S., Hanus L., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
21. Sugiura T., Kondo S., Sukagawa A., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 (1995) 89-97
22. Hanus L., Abu-Lafi S., Fride E., et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98 (2001) 3662-3665
23. Porter A.C., Sauer J.M., Knierman M.D., et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301 (2002) 1020-1024
24. Huang S.M., Bisogno T., Trevisani M., et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99 (2002) 8400-8405
25. Fezza F., De Simone C., Amadio D., and Maccarrone M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem 49 (2008) 101-132
26. Lo Verme J., Fu J., Astarita G., et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67 (2005) 15-19
27. Re G., Barbero R., Miolo A., and Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 173 (2007) 21-30
28. Bisogno T., De Petrocellis L., and Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 8 (2002) 533-547
29. Cravatt B.F., Demarest K., Patricelli M.P., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98 (2001) 9371-9376
30. Lichtman A.H., Shelton C.C., Advani T., and Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109 (2004) 319-327
31. Ross R.A., Gibson T.M., Brockie H.C., et al. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 132 (2001) 631-640
32. Bouaboula M., Hilairet S., Marchand J., Fajas L., Le Fur G., and Casellas P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517 (2005) 174-181
33. Hohmann A.G., Suplita R.L., Bolton N.M., et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 435 (2005) 1108-1112
34. Dinh T.P., Carpenter D., Leslie F.M., et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99 (2002) 10819-10824
35. Dixon W.E. The pharmacology of Cannabis indica. BMJ 2 (1899) 1354-1357
36. Walker J.M., and Hohmann A.G. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol (2005) 509-554
37. Bennett G.J., and Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
38. Lim G., Sung B., Ji R.R., and Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105 (2003) 275-283
39. Wang S., Lim G., Mao J., Sung B., Yang L., and Mao J. Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats. Pain 131 (2007) 96-105
40. Costa B., Trovato A.E., Comelli F., Giagnoni G., and Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556 (2007) 75-83
41. Comelli F., Giagnoni G., Bettoni I., Colleoni M., and Costa B. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother Res 22 (2008) 1017-1024
42. Herzberg U., Eliav E., Bennett G.J., and Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221 (1997) 157-160
43. Costa B., Trovato A.E., Colleoni M., Giagnoni G., Zarini E., and Croci T. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116 (2005) 52-61
44. Ibrahim M.M., Deng H., Zvonok A., et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100 (2003) 10529-10533
45. Sain N.M., Liang A., Kane S.A., and Urban M.O. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain. Neuropharmacology 57 (2009) 235-241
46. Strangman N.M., and Walker J.M. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 82 (1999) 472-477
47. Liu C., and Walker J.M. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. J Neurophysiol 96 (2006) 2984-2994
48. Costa B., Colleoni M., Conti S., et al. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 141 (2004) 4-8
49. Zhang J., Hoffert C., Vu H.K., Groblewski T., Ahmad S., and O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17 (2003) 2750-2754
50. Hu B., Doods H., Treede R.D., and Ceci A. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain (2009)
51. Yao B.B., Hsieh G., Daza A.V., et al. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 328 (2009) 141-151
52. Costa B., Siniscalco D., Trovato A.E., et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol 148 (2006) 1022-1032
53. La Rana G., Russo R., Campolongo P., et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther 317 (2006) 1365-1371
54. La Rana G., Russo R., D'Agostino G., et al. AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: role for cannabinoid receptors. Neuropharmacology 54 (2008) 521-529
55. Russo R., Loverme J., La Rana G., et al. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322 (2007) 236-242
56. Petrosino S., Palazzo E., de Novellis V., et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52 (2007) 415-422
57. Palazzo E., de Novellis V., Petrosino S., et al. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur J Neurosci 24 (2006) 2011-2020
58. Rodella L.F., Borsani E., Rezzani R., Ricci F., Buffoli B., and Bianchi R. AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. Eur J Pharmacol 508 (2005) 139-146
59. Kinsey S.G., Long J.Z., O'Neal S.T., et al. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther (2009)
60. Costa B., Comelli F., Bettoni I., Colleoni M., and Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain (2008)
61. Seltzer Z., Dubner R., and Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43 (1990) 205-218
62. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., and Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147 (2006) 281-288
63. Racz I., Nadal X., Alferink J., et al. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 28 (2008) 12125-12135
64. Wallace V.C., Segerdahl A.R., Lambert D.M., et al. The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. Br J Pharmacol 151 (2007) 1117-1128
65. Helyes Z., Nemeth J., Than M., Bolcskei K., Pinter E., and Szolcsanyi J. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 73 (2003) 2345-2353
66. Guindon J., and Beaulieu P. Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50 (2006) 814-823
67. Desroches J., Guindon J., Lambert C., and Beaulieu P. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 155 (2008) 913-924
68. Fox A., Kesingland A., Gentry C., et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92 (2001) 91-100
69. Dyson A., Peacock M., Chen A., et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 116 (2005) 129-137
70. Yamamoto W., Mikami T., and Iwamura H. Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 583 (2008) 56-61
71. Racz I., Nadal X., Alferink J., et al. Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J Neurosci 28 (2008) 12136-12145
72. Staton P.C., Hatcher J.P., Walker D.J., et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139 (2008) 225-236
73. Mitchell V.A., Greenwood R., Jayamanne A., and Vaughan C.W. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin Exp Pharmacol Physiol 34 (2007) 1186-1190
74. Lambert D.M., and Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Curr Med Chem 6 (1999) 757-773
75. Vuong L.A., Mitchell V.A., and Vaughan C.W. Actions of N-arachidonyl-glycine in a rat neuropathic pain model. Neuropharmacology 54 (2008) 189-193
76. Dani M., Guindon J., Lambert C., and Beaulieu P. The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. Eur J Pharmacol 573 (2007) 214-215
77. Kim S.H., and Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50 (1992) 355-363
78. De Vry J., Denzer D., Reissmueller E., et al. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfo nate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J Pharmacol Exp Ther 310 (2004) 620-632
79. Bridges D., Ahmad K., and Rice A.S. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133 (2001) 586-594
80. LaBuda C.J., and Little P.J. Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J Neurosci Methods 144 (2005) 175-181
81. Leichsenring A., Andriske M., Backer I., Stichel C.C., and Lubbert H. Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol 379 (2009) 627-636
82. Chapman V. Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology 41 (2001) 870-877
83. Mitrirattanakul S., Ramakul N., Guerrero A.V., et al. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126 (2006) 102-114
84. Kawasaki Y., Kohno T., and Ji R.R. Different effects of opioid and cannabinoid receptor agonists on C-fiber-induced extracellular signal-regulated kinase activation in dorsal horn neurons in normal and spinal nerve-ligated rats. J Pharmacol Exp Ther 316 (2006) 601-607
85. Naguib M., Diaz P., Xu J.J., et al. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol 155 (2008) 1104-1116
86. Elmes S.J., Jhaveri M.D., Smart D., Kendall D.A., and Chapman V. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20 (2004) 2311-2320
87. Jhaveri M.D., Elmes S.J., Richardson D., et al. Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. Eur J Neurosci 27 (2008) 1722-1730
88. McGaraughty S., Chu K.L., Dart M.J., Yao B.B., and Meyer M.D. A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors. Neuroscience 158 (2009) 1652-1661
89. Rahn E.J., Zvonok A.M., Thakur G.A., Khanolkar A.D., Makriyannis A., and Hohmann A.G. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 327 (2008) 584-591
90. Sit S.Y., Conway C., Bertekap R., et al. Novel inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 17 (2007) 3287-3291
91. Chang L., Luo L., Palmer J.A., et al. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148 (2006) 102-113
92. Jhaveri M.D., Richardson D., Kendall D.A., Barrett D.A., and Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26 (2006) 13318-13327
93. Vos B.P., and Maciewicz R. Behavioral changes following ligation of the infraorbital nerve in rats: an animal model of trigeminal neuropathic pain. In: Besson J.M., and Guilbaud G. (Eds). Lesions of primary afferent fibers as a tool for the study of clinical pain (1991), Elsevier, Amsterdam 147-158
94. Liang Y.C., Huang C.C., and Hsu K.S. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology 53 (2007) 169-177
95. Liang Y.C., Huang C.C., Hsu K.S., and Takahashi T. Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices. J Physiol 555 (2004) 85-96
96. Romero-Sandoval A., Nutile-McMenemy N., and DeLeo J.A. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 108 (2008) 722-734
97. Tanga F.Y., Nutile-McMenemy N., and DeLeo J.A. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A 102 (2005) 5856-5861
98. Walczak J.S., Pichette V., Leblond F., Desbiens K., and Beaulieu P. Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 132 (2005) 1093-1102
99. Walczak J.S., Pichette V., Leblond F., Desbiens K., and Beaulieu P. Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 83 (2006) 1310-1322
100. Decosterd I., and Woolf C.J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87 (2000) 149-158
101. Decosterd I., Allchorne A., and Woolf C.J. Differential analgesic sensitivity of two distinct neuropathic pain models. Anesth Analg 99 (2004) 457-463
102. Bruce J.C., Oatway M.A., and Weaver L.C. Chronic pain after clip-compression injury of the rat spinal cord. Exp Neurol 178 (2002) 33-48
103. Hama A., and Sagen J. Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury. Exp Neurol 204 (2007) 454-457
104. Hama A., and Sagen J. Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain. J Rehabil Res Dev 46 (2009) 135-143
105. Hofmann H.A., De Vry J., Siegling A., Spreyer P., and Denzer D. Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain. Eur J Pharmacol 470 (2003) 17-25
106. Siegling A., Hofmann H.A., Denzer D., Mauler F., and De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415 (2001) R5-R7
107. Bujalska M. Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy. Pharmacology 82 (2008) 193-200
108. Zhang F., Hong S., Stone V., and Smith P.J. Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J Pharmacol Exp Ther 323 (2007) 508-515
109. Matias I., Wang J.W., Moriello A.S., Nieves A., Woodward D.F., and Di Marzo V. Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukot Essent Fatty Acids 75 (2006) 413-418
110. Engeli S., Bohnke J., Feldpausch M., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
111. Murdolo G., Kempf K., Hammarstedt A., Herder C., Smith U., and Jansson P.A. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest 30 (2007) RC17-RC21
112. Scheen A.J. The endocannabinoid system: a promising target for the management of type 2 diabetes. Curr Protein Pept Sci 10 (2009) 56-74
113. Watanabe T., Kubota N., Ohsugi M., et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 284 (2009) 1803-1812
114. Dagon Y., Avraham Y., Link G., Zolotarev O., Mechoulam R., and Berry E.M. The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells. Neurobiol Dis 27 (2007) 174-181
115. Williams J., Haller V.L., Stevens D.L., and Welch S.P. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. Eur J Pharmacol 584 (2008) 78-86
116. Vera G., Chiarlone A., Cabezos P.A., Pascual D., Martin M.I., and Abalo R. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 81 (2007) 468-479
117. Ray A.P., Griggs L., and Darmani N.A. Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav Brain Res 196 (2009) 30-36
118. Polomano R.C., Mannes A.J., Clark U.S., and Bennett G.J. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94 (2001) 293-304
119. Pascual D., Goicoechea C., Suardiaz M., and Martin M.I. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118 (2005) 23-34
120. Flatters S.J., and Bennett G.J. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 109 (2004) 150-161
121. Weng H.R., Cordella J.V., and Dougherty P.M. Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 103 (2003) 131-138
122. Rahn E.J., Makriyannis A., and Hohmann A.G. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 152 (2007) 765-777
123. Wallace V.C., Blackbeard J., Segerdahl A.R., et al. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain 130 (2007) 2688-2702
124. Wallace V.C., Blackbeard J., Pheby T., et al. Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain 133 (2007) 47-63
125. Wallace V.C., Cottrell D.F., Brophy P.J., and Fleetwood-Walker S.M. Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci 23 (2003) 3221-3233
126. Lynch J.L., Gallus N.J., Ericson M.E., and Beitz A.J. Analysis of nociception, sex and peripheral nerve innervation in the TMEV animal model of multiple sclerosis. Pain 136 (2008) 293-304
127. Buchanan R.J., Wang S., and Ju H. Gender analyses of nursing home residents with multiple sclerosis. J Gend Specif Med 6 (2003) 35-46
128. Olechowski C.J., Truong J.J., and Kerr B.J. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain 141 (2009) 156-164
129. Loria F., Petrosino S., Mestre L., et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 28 (2008) 633-641
130. LoVerme J., Russo R., La Rana G., et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319 (2006) 1051-1061
131. Hasnie F.S., Breuer J., Parker S., et al. Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience 144 (2007) 1495-1508
132. Beaulieu P., and Ware M. Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol 20 (2007) 473-477
133. Nurmikko T.J., Serpell M.G., Hoggart B., Toomey P.J., Morlion B.J., and Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133 (2007) 210-220
134. Svendsen K.B., Jensen T.S., and Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis?. Randomised double blind placebo controlled crossover trial. BMJ 329 (2004) 253
135. Abrams D.I., Jay C.A., Shade S.B., et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68 (2007) 515-521
136. Abrams D.I., Hilton J.F., Leiser R.J., et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 139 (2003) 258-266
137. Ellis R.J., Toperoff W., Vaida F., et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34 (2009) 672-680
138. Woolridge E., Barton S., Samuel J., Osorio J., Dougherty A., and Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 29 (2005) 358-367
139. Beal J.E., Olson R., Laubenstein L., et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10 (1995) 89-97
140. Vincent B.J., McQuiston D.J., Einhorn L.H., Nagy C.M., and Brames M.J. Review of cannabinoids and their antiemetic effectiveness. Drugs 25 suppl 1 (1983) 52-62
141. Tramer M.R., Carroll D., Campbell F.A., Reynolds D.J., Moore R.A., and McQuay H.J. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323 (2001) 16-21
142. Malfitano A.M., Proto M.C., and Bifulco M. Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat 4 (2008) 847-853
143. Zajicek J., Fox P., Sanders H., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362 (2003) 1517-1526
144. Mechoulam R., Peters M., Murillo-Rodriguez E., and Hanus L.O. Cannabidiol-recent advances. Chem Biodivers 4 (2007) 1678-1692
145. Zajicek J.P., Sanders H.P., Wright D.E., et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76 (2005) 1664-1669
146. Rog D.J., Nurmikko T.J., Friede T., and Young C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65 (2005) 812-819
147. Rog D.J., Nurmikko T.J., and Young C.A. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29 (2007) 2068-2079
148. Iskedjian M., Bereza B., Gordon A., Piwko C., and Einarson T.R. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 23 (2007) 17-24
149. Yiangou Y., Facer P., Durrenberger P., et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6 (2006) 12
150. Berman J.S., Symonds C., and Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112 (2004) 299-306
151. Anand U., Otto W.R., Sanchez-Herrera D., et al. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 138 (2008) 667-680
152. Karst M., Salim K., Burstein S., Conrad I., Hoy L., and Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290 (2003) 1757-1762
153. Salim K., Schneider U., Burstein S., Hoy L., and Karst M. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 48 (2005) 1164-1171
154. Liu J., Li H., Burstein S.H., Zurier R.B., and Chen J.D. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 63 (2003) 983-992
155. Wilsey B., Marcotte T., Tsodikov A., et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 9 (2008) 506-521
156. Notcutt W., Price M., Miller R., et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59 (2004) 440-452
157. Walker J.M., Farney R.J., Rhondeau S.M., et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 3 (2007) 455-461
158. Dimsdale J.E., Norman D., DeJardin D., and Wallace M.S. The effect of opioids on sleep architecture. J Clin Sleep Med 3 (2007) 33-36
159. Wade D.T., Robson P., House H., Makela P., and Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17 (2003) 21-29
160. Wissel J., Haydn T., Muller J., et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 253 (2006) 1337-1341
161. Berlach D.M., Shir Y., and Ware M.A. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med 7 (2006) 25-29
162. Maurer M., Henn V., Dittrich A., and Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 240 (1990) 1-4
163. Hagenbach U., Luz S., Ghafoor N., et al. The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 45 (2007) 551-562
164. Attal N., Brasseur L., Guirimand D., Clermond-Gnamien S., Atlami S., and Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain?. Eur J Pain 8 (2004) 173-177
165. Clermont-Gnamien S., Atlani S., Attal N., Le Mercier F., Guirimand F., and Brasseur L. The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain. Presse Med 31 (2002) 1840-1845
166. Frank B., Serpell M.G., Hughes J., Matthews J.N., and Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. Bmj 336 (2008) 199-201
167. Pinsger M., Schimetta W., Volc D., Hiermann E., Riederer F., and Polz W. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain-a randomized controlled trial. Wien Klin Wochenschr 118 (2006) 327-335
168. Narang S., Gibson D., Wasan A.D., et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 9 (2008) 254-264
169. Toth C., and Au S. A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy. Pain 138 (2008) 657-666
170. Wang T., Collet J.P., Shapiro S., and Ware M.A. Adverse effects of medical cannabinoids: a systematic review. CMAJ 178 (2008) 1669-1678
171. De Vry J., Kuhl E., Franken-Kunkel P., and Eckel G. Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol 491 (2004) 137-148
172. Pedersen L.H., and Blackburn-Munro G. Pharmacological characterisation of place escape/avoidance behaviour in the rat chronic constriction injury model of neuropathic pain. Psychopharmacology (Berl) 185 (2006) 208-217
173. Hama A.T., and Urban M.O. Antihyperalgesic effect of the cannabinoid agonist WIN55,212-2 is mediated through an interaction with spinal metabotropic glutamate-5 receptors in rats. Neurosci Lett 358 (2004) 21-24
174. Yao B.B., Hsieh G.C., Frost J.M., et al. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 153 (2008) 390-401
175. Mitchell V.A., Aslan S., Safaei R., and Vaughan C.W. Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain. Neurosci Lett 382 (2005) 231-235
176. Guindon J., Desroches J., Dani M., and Beaulieu P. Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain. Eur J Pharmacol 568 (2007) 173-176
177. Valenzano K.J., Tafesse L., Lee G., et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48 (2005) 658-672
178. Whiteside G.T., Gottshall S.L., Boulet J.M., et al. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol 528 (2005) 65-72
179. Scott D.A., Wright C.E., and Angus J.A. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109 (2004) 124-131
180. Worm K., Zhou Q.J., Saeui C.T., et al. Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands. Bioorg Med Chem Lett 18 (2008) 2830-2835
181. Diaz P., Xu J., Astruc-Diaz F., Pan H.M., Brown D.L., and Naguib M. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. J Med Chem 51 (2008) 4932-4947
182. Dogrul A., Gul H., Yildiz O., Bilgin F., and Guzeldemir M.E. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 368 (2004) 82-86
183. Ulugol A., Karadag H.C., Ipci Y., Tamer M., and Dokmeci I. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 371 (2004) 167-170